Life sciences panel pegs bright spots in Indiana
Leaders tackle issues ranging from research to cold storage to the future of Eli Lilly and Co.
Eli Lilly and Co.
Articles
For Lilly, it’s a big one that got away
An experimental medicine for hepatitis C that Lilly helped identify and develop is now on the cusp of market approval, with
analysts predicting as much as $2 billion in annual U.S. sales.
Court defeat lost in Lilly’s gloomy long-term outlook
Eli Lilly and Co.’s loss of a patent on one of its blockbuster drugs in court late last month received a collective yawn
from
investors, who have shunned the stock because of five looming patent expirations.
Lilly among bidders for Denmark company, source says
Copenhagen-based health-care company Ascendis Pharma A/S received offers of about $400 million, an unidentified source said.
Ascendis may choose a final bidder by early September.
Lilly loses appeal over patent for cancer drug Gemzar
A U.S. appeals court Wednesday said a lower court was correct to invalidate a patent on the medicine that expires in 2013.
Gemzar generated $1.36 billion in global sales in 2009.
UPDATE: Patent expirations overshadow Lilly profits
Investors are focused on whether Eli Lilly and Co. can continue dividend payments when patent expirations hit in the new few
years and whether the company's drug development pipeline can replace lost revenue.
Lilly’s second-quarter profits surge 16 percent
Indianapolis-based drugmaker Eli Lilly and Co. recorded profits of $1.3 billion, or $1.22 per share, during the three months
ended June 30,
even after paying $27 million in severance to laid off employees.
Lilly completes $180 million acquisition of Alnara
Massachusetts-based Alnara Pharmaceuticals Inc. is a privately held company
developing an enzyme-replacement therapy for disorders of the pancreas.
New rules raise stakes for Lilly drug
Drugmakers testing experimental Alzheimer’s medicines—including Eli Lilly and Co.—got good news last week
when the National Institute on Aging and the Alzheimer’s Association proposed new guidelines to make earlier diagnoses
of the disease.
Lilly reveals plans to cut 340 IT jobs
The Indianapolis-based drugmaker eliminated 140 information technology jobs in June through retirements, resignations and some cuts. Another 115
cuts will be made this month, and the remainder by the end of the year.
Lilly, Roche dive deep into diagnostics
Two Indianapolis giants—Eli Lilly and Co. and Roche Diagnostics—are working hard to pair up drugs and diagnostic
tests to gin up more sales.
Lilly’s Alzheimer’s gamble takes aim at $10 billion in patent losses
Both of Lilly’s late-stage treatments are designed to reduce plaque in the brain called beta amyloid, thought by researchers
to be a main contributor to Alzheimer’s. A drug that stops or reduces memory loss caused by Alzheimer’s may be worth more
than $5 billion
a year, an analyst says, helping Lilly overcome the coming patent losses on several important pharmaceuticals.
Lilly to cut 170 manufacturing jobs by year’s end
Eli Lilly and Co. will cut 170 jobs—mostly in Indianapolis—from its manufacturing and quality division by the
end of the year as it continues its efforts to slim down before losing revenue from patent expirations on its bestselling
drugs.
Diagnostics division to help Lilly tailor treatments
Eli Lilly and Co. is launching a diagnostics division to produce tests that can winnow out the patients most likely to benefit
from a Lilly drug.
Lilly’s Lechleiter: No change in plans
The global financial press keeps asking John Lechleiter for his end-game strategy to survive Eli Lilly and Co.'s nightmarish
patent challenges. And, like a broken record, the Lilly CEO keeps giving the same answer: pipeline, pipeline, pipeline—no
mega-merger.
Men on Viagra, Cialis show triple rate of sex diseases in study
The findings suggest that users of drugs to treat erectile dysfunction, including Eli Lilly’s Cialis, may be more likely to
engage in unsafe sex than nonusers.
Lilly acquires biotech company with pancreatic drug
Massachusetts-based Alnara Pharmaceuticals Inc., which has attracted $55 million in venture capital in the past two years,
recently submitted its drug to the FDA for market approval.
Grassley asks Lilly, peers about whistleblower treatment
U.S. Senator Charles Grassley asked 16 drugmakers, including Eli Lilly & Co., Pfizer Inc. and AstraZeneca Plc, to reveal
how they treat whistleblowers who file complaints under the False Claims Act.
Lilly’s Effient steps forward, then back
A day after doctors were alerted to a black-box warning that could slow sales of Effient’s main competitor,
Plavix,
a medical journal published research showing that patients suffered 43-percent more cancer tumors on Effient than on Plavix.
Marcadia enlists Lilly to help develop new diabetes drug
The two companies will jointly develop a short-acting glucagon drug, which they hope proves more convenient than Lilly’s
current Glucagon for patients with severe hypoglycemia.